bluebird bio Inc
NASDAQ:BLUE
bluebird bio Inc
Cash from Financing Activities
bluebird bio Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
bluebird bio Inc
NASDAQ:BLUE
|
Cash from Financing Activities
$129.9m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
2%
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is bluebird bio Inc's Cash from Financing Activities?
Cash from Financing Activities
129.9m
USD
Based on the financial report for Sep 30, 2023, bluebird bio Inc's Cash from Financing Activities amounts to 129.9m USD.
What is bluebird bio Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
2%
The average annual Cash from Financing Activities growth rates for bluebird bio Inc have been -38% over the past three years , -37% over the past five years , and 2% over the past ten years .